Novo Nordisk is planning to initiate by midyear a pivotal Phase 3a trial of oral semaglutide, a diabetes treatment, in people with early Alzheimer’s disease. “As a company we aspire to address high unmet medical needs within serious chronic diseases, and we are therefore pleased to initiate phase 3 development of semaglutide within Alzheimer’s disease,” Mads Krogsgaard Thomsen, PhD, executive vice president and chief scientific officer at Novo Nordisk, said in a press release. Semaglutide is…
You must be logged in to read/download the full post.
The post Phase 3 Trial of Diabetes Treatment in Early Alzheimer’s Patients Planned appeared first on BioNewsFeeds.